Thomas Bures is the Sr. VP & CFO at Pieris Pharmaceuticals Inc.
As the Sr. VP & CFO of Pieris Pharmaceuticals Inc, the total compensation of Mr Bures at Pieris Pharmaceuticals Inc is $360,506. There are 6 executives at Pieris Pharmaceuticals Inc getting paid more, with Stephen Yoder having the highest compensation of $1,593,600.
Mr Bures is 47, he's been the Sr. VP & CFO of Pieris Pharmaceuticals Inc since . There are 8 older and 8 younger executives at Pieris Pharmaceuticals Inc. The oldest executive at Pieris Pharmaceuticals Inc is Peter Kiener, 68, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O PIERIS PHARMACEUTICALS, INC., 225 FRANKLIN STREET, 26TH FLOOR, BOSTON, MA, 02110.
Over the last 9 years, insiders at Pieris Pharmaceuticals Inc have traded over $24,745,707 worth of Pieris Pharmaceuticals Inc stock and bought 1,154,000 units worth $3,376,410 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Advisors Llc Orbi Med Capit..., and Chau Quang Khuong. On average, Pieris Pharmaceuticals Inc executives and independent directors trade stock every 144 days with the average trade being worth of $4,572,148. The most recent stock trade was executed by Capital Management, Llcadar... on 9 August 2024, trading 6,000 units of PIRS stock currently worth $92,340.
pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche
Pieris Pharmaceuticals Inc executives and other stock owners filed with the SEC include: